Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immunotherapy for conformational diseases.

Einar M Sigurdsson¹

¹New York University, School of Medicine, Department of Psychiatry, Millhauser Laboratories, HN418, 560 First Avenue, New York, NY 10016, USA. einar.sigurdsson@med.nyu.edu

Current Pharmaceutical Design

|July 18, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cell-Type-Selective Cortical Pathology and Functional Deficits in Synucleinopathy.

bioRxiv : the preprint server for biology·2026

Same author

Tau pSer396 and pSer404 Define Distinct Epitope Regions Linked to Different Antibody Functions.

bioRxiv : the preprint server for biology·2026

Same author

Autophagosome-targeting single-domain antibody clears tau in patient-derived neurons and improves motor function in tauopathy mice.

Science translational medicine·2026

Same author

Corrigendum to "Formaldehyde induces and promotes Alzheimer's disease pathologies in a 3D human neural cell culture model" [Food Chem. Toxicol. (2025 Dec) 206 115777].

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2025

Same author

Formaldehyde induces and promotes Alzheimer's disease pathologies in a 3D human neural cell culture model.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2025

Same author

Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice.

Cell reports·2025

Immunotherapy targeting amyloid-beta 1-42 shows promise for Alzheimer's disease and other protein disorders. Despite early setbacks in human trials, ongoing research in animal models suggests potential for cognitive improvement and disease clearance.

Area of Science:

Neuroscience
Immunology
Pharmacology

Background:

Alzheimer's disease (AD) is characterized by amyloid plaque accumulation.
Immunization targeting amyloid-beta 1-42 has shown potential in AD mouse models.
Clinical trials in AD patients faced challenges due to adverse effects.

Purpose of the Study:

To explore the potential of immunotherapy for Alzheimer's disease and other conformational degenerative disorders.
To evaluate refined immunotherapy approaches in animal models.
To assess the efficacy of immunotherapy in prion disease models.

Main Methods:

Immunization with amyloid-beta 1-42 in animal models.
Assessment of amyloid plaque formation and clearance.
Evaluation of cognitive improvements in animal models.

Related Experiment Videos

Analysis of immunotherapy in prion disease models.

Main Results:

Immunization prevented or cleared amyloid plaques in AD mouse models.
Refined immunotherapy approaches led to cognitive improvements in animal models.
Positive results were observed in prion disease models, suggesting broader applicability.

Conclusions:

Immunotherapy targeting amyloid-beta remains a promising strategy for Alzheimer's disease.
This approach shows potential for treating various protein-related disorders, including prion diseases.
Further research and refinement of immunotherapy are warranted to mitigate side effects and enhance efficacy.